MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Clinical trial NCT06152575 · RECRUITING
Trial details
- NCT number
- NCT06152575
- Sponsor
- Pfizer
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-08
- Primary completion
- 2026-08-30
- Enrollment
- 492
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.